Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC has released a White Paper "Reimbursement Pathways for Companion Diagnostic (CDx) Tests in Europe"

MTRC is pleased to announce the release of its latest White Paper: "Reimbursement Pathways for Companion Diagnostic (CDx) Tests in Europe".

MTRC’s latest White Paper provides a comprehensive overview of the reimbursement landscape for CDx tests in five largest European countries: England, France, Germany, Italy, and Spain. It outlines payment mechanisms in both hospital and ambulatory care settings, the need for explicit approval by payers, the role of health technology assessments (HTA) in decision-making. An illustrative case study explores the reimbursement status of the Oncotype DX Breast Recurrence Score Test in five countries. 

This publication is designed to support med tech professionals, particularly those in the IVD and pharmaceutical fields, in navigating the complex and evolving companion diagnostic reimbursement landscape across Europe and shaping effective market access strategies.

Read more and request a White Paper here.